Sanofi (SNY,SAN.PA) has entered into an agreement to acquire Dynavax Technologies, a publicly traded vaccines company with a marketed adult hepatitis B vaccine and differentiated shingles vaccine candidate. Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Sanofi noted that the agreement is not expected to have any impact on Sanofi's financial guidance for 2025.
Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month. The acquisition also includes Dynavax's shingles vaccine candidate, Z-1018, which is currently in phase 1/2 clinical development and additional vaccine pipeline projects.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.